Welcome to our dedicated page for Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares news (Ticker: CANF), a resource for investors and traders seeking the latest updates and insights on Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares stock.
Can-Fite BioPharma Ltd. (symbol: CANF) is a clinical-stage biopharmaceutical company headquartered at 10 Bareket Street, פ"ת, Israel. This biotechnology firm specializes in the development of orally bioavailable small molecule therapeutic products aimed at treating a range of conditions including cancer, liver, and inflammatory diseases.
The company leverages its proprietary platform technology, which targets the Gi protein associated A3 adenosine receptor (A3AR) to develop its therapeutic candidates. One of its leading drug candidates, Piclidenoson, is currently undergoing a Phase III clinical trial for psoriasis, indicating its advanced stage in the development pipeline.
Another significant product in Can-Fite's portfolio is Namodenoson. This drug is making strides towards addressing liver-related conditions, with a Phase III trial underway for hepatocellular carcinoma (HCC), the most common form of liver cancer. Additionally, it is in a Phase IIb trial for non-alcoholic steatohepatitis (NASH), a serious liver condition with limited treatment options.
Can-Fite BioPharma is committed to improving patient outcomes through innovative therapeutic solutions. The company collaborates with various partners and research institutions to drive its drug development programs forward. Its focus on oral therapeutics provides an added advantage of ease of administration, potentially improving patient compliance and overall treatment efficacy.
This combination of advanced clinical trials, strategic partnerships, and a focused therapeutic approach highlights Can-Fite BioPharma's role as a significant player in the biopharmaceutical industry.
Can-Fite BioPharma has provided an update on the pivotal Phase 3 study for Namodenoson, its lead drug candidate for advanced liver cancer. The study involves 31 medical centers across Europe, Israel, and the US, with Namodenoson holding Orphan Drug and Fast Track status from the FDA.
The compassionate use program is ongoing in Israel and Romania. Previous Phase 2 results showed that Namodenoson prolonged survival and improved quality of life in patients, with some achieving long-term complete responses.
The Phase 3 LIVERATION trial will enroll 450 patients with advanced liver cancer and Child Pugh B7 cirrhosis, comparing Namodenoson to a placebo. The trial's primary endpoint is overall survival, with interim analysis by an Independent Data Monitoring Committee after 50% enrollment.
Liver cancer causes over 700,000 deaths annually, with the HCC treatment market projected to reach $3.8 billion by 2027.
Can-Fite BioPharma announced that the International Journal of Molecular Sciences published a review highlighting the positive effects of its drugs, piclidenoson and namodenoson, on heart diseases. The review, based on over 50 publications, showed that these drugs improved outcomes in pre-clinical studies, such as reducing infarct size and protecting against ischemic injury. Dr. Pnina Fishman noted the drugs' cardio-protective potential and their good safety profile observed in over 1600 patients. Can-Fite is also advancing clinical studies in psoriasis, liver cancer, MASH, and pancreatic cancer.
Can-Fite BioPharma announced that its VP of Business Development, Dr. Sari Fishman, will engage in 23 partnering meetings at the Bio International Convention 2024 in San Diego from June 3-6. These meetings aim to explore potential collaborations with biotech and pharma companies. Can-Fite has existing out-licensing and distribution agreements with seven pharma companies across North America, Europe, and Asia. The company is currently developing two small molecule drugs: Piclidenoson for psoriasis (Phase 3) and Namodenoson for advanced liver cancer (Phase 3), pancreatic cancer (Phase 2a), and NASH (Phase 2b).
Can-Fite BioPharma (NYSE American: CANF; TASE: CANF), a biotechnology firm focused on small molecule drugs for oncological and inflammatory diseases, invites investors to a webinar on June 6, 2024, at 4:15 p.m. ET.
Hosted by RedChip Companies, the event will feature CEO Motti Farbstein and Executive Chairperson/Chief Scientific Officer Pnina Fishman, PhD. They will discuss the company's current development pipeline and upcoming milestones.
Investors can register for the free webinar and pre-submit questions at the provided link.
Can-Fite BioPharma held a conference for 75 oncologists and coordinators to accelerate patient enrollment for the pivotal Phase 3 advanced liver cancer study. The study aims to evaluate Namodenoson as a 2nd or 3rd line treatment for CPB7 patients with HCC. The drug has Orphan Drug status and Fast Track Status with the FDA for HCC treatment. The market for HCC treatments is projected to reach $6.1 billion by 2027.
RedChip Companies will air interviews with Can-Fite BioPharma (NYSE American:CANF) and Nutriband Inc. (NASDAQ:NTRB) on the RedChip Small Stocks, Big Money™ show on Bloomberg TV. Pnina Fishman, Executive Chairperson and Chief Scientific Officer of Can-Fite BioPharma, discusses the company's advanced clinical stage drug development focusing on oncology and inflammatory diseases. Can-Fite has two drug candidates in advanced stages of development with registration plans agreed with the U.S. FDA and the EMA. Gareth Sheridan, Founder and CEO of Nutriband, talks about their AVERSA™ abuse-deterrent transdermal technology to address the global opioid crisis. Nutriband's lead product, AVERSA™ Fentanyl, is targeting peak annual sales of $80 million to $200 million.
Can-Fite BioPharma has received FDA clearance for its small molecule drug, Namodenoson, to treat MASH patients in a Phase IIb study. The drug targets the A3 adenosine receptor in liver cells, showing promise in reducing hepatic steatosis, inflammation, and fibrosis. The Phase IIb trial aims to evaluate Namodenoson's efficacy in 140 MASH patients, with enrollment now open in the US.
Can-Fite BioPharma (NYSE American: CANF) received a Notice of Allowance from the European Patent Office for its patent application related to the use of the CF602 drug candidate for the treatment of erectile dysfunction in patients such as diabetics. The patent has already been issued in other major markets. Can-Fite's CF602 showed promising results in a diabetic rat model, offering an alternative for non-responders to current ED drugs. The company sees this as a significant addition to their IP estate, positioning CF602 as a potential treatment for sexual dysfunction.
FAQ
What is the current stock price of Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares (CANF)?
What is the market cap of Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares (CANF)?
What does Can-Fite BioPharma Ltd. specialize in?
Where is Can-Fite BioPharma Ltd. located?
What is Piclidenoson?
What is Namodenoson used for?
What stage are the trials for Namodenoson?
What is the A3 adenosine receptor (A3AR)?
How does Can-Fite BioPharma's technology benefit patients?
What is the significance of Can-Fite BioPharma's partnerships?
Is Can-Fite BioPharma listed on any stock exchange?
What is the focus of Can-Fite BioPharma's current projects?
